Intra-Cellular Therapies
ITCI
$67.24
Share price
2.42%
Change (1 day)
12.95%
Change (1 year)
Categories
Intra-Cellular Therapies (ITCI) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $0.14 B
According to Intra-Cellular Therapies's latest financial reports the company's total liabilities are $0.14 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Intra-Cellular Therapies - Total liabilities on balance sheet (from 2013 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.13 B | 38.66% |
| 2022-12-31 | $98.71 M | 37.04% |
| 2021-12-31 | $72.03 M | 19.15% |
| 2020-12-31 | $60.45 M | 7.61% |
| 2019-12-31 | $56.17 M | 42.26% |
| 2018-12-31 | $39.49 M | 131.63% |
| 2017-12-31 | $17.04 M | 27.23% |
| 2016-12-31 | $13.4 M | 70.48% |
| 2015-12-31 | $7.86 M | -25.54% |
| 2014-12-31 | $10.55 M | 54.48% |
| 2013-12-31 | $6.83 M | 140.67% |
| 2013-03-31 | $0.02 M | |
| 2012-12-31 | $2.83 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | $0.27 B | 84.41% | 🇺🇸 USA |
 MediciNova MNOV | $3.06 M | -97.92% | 🇺🇸 USA |
 Curis CRIS | $52.56 M | -64.37% | 🇺🇸 USA |